Addex Therapeutics in the spotlight

Diminished enthusiasm in $ADXN

Earlier today (02/06/2023), Addex (ADXN) announced that Janssen has completed the enrollment of Part 1 of their Phase 2 clinical study of ADX71149 in epilepsy. Data from Part 1 will now be evaluated by an independent interim review committee (IRC) to ensure the study remains blinded. Based on the outcome of this review and recommendations from the IRC, …